Atara Biotherapeutics, Inc. - 8-K Filing
Atara Biotherapeutics notified Yanina Grant-Huerta, its Chief Accounting Officer, that her employment would end on July 17, 2026. On June 26, 2026, the company appointed Kevin G. Sarney of Charles River CFO as interim chief financial officer and principal accounting officer under a consulting agreement. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Offic)
Tickers: $ATRA